- Home
- MSC vs MESO Comparison
MSC vs MESO Comparison
Compare MSC & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSC
- MESO
- Stock Information
- Founded
- MSC 2000
- MESO 2004
- Country
- MSC Hong Kong
- MESO Australia
- Employees
- MSC N/A
- MESO N/A
- Industry
- MSC Hotels/Resorts
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MSC Consumer Discretionary
- MESO Health Care
- Exchange
- MSC Nasdaq
- MESO Nasdaq
- Market Cap
- MSC 1.2B
- MESO 1.1B
- IPO Year
- MSC 2018
- MESO N/A
- Fundamental
- Price
- MSC $6.22
- MESO $10.04
- Analyst Decision
- MSC
- MESO Strong Buy
- Analyst Count
- MSC 0
- MESO 4
- Target Price
- MSC N/A
- MESO $11.50
- AVG Volume (30 Days)
- MSC 5.8K
- MESO 204.9K
- Earning Date
- MSC 11-05-2024
- MESO 08-28-2024
- Dividend Yield
- MSC N/A
- MESO N/A
- EPS Growth
- MSC N/A
- MESO N/A
- EPS
- MSC N/A
- MESO N/A
- Revenue
- MSC $627,533,000.00
- MESO $5,902,000.00
- Revenue This Year
- MSC $33.86
- MESO $66.05
- Revenue Next Year
- MSC $16.73
- MESO $348.27
- P/E Ratio
- MSC N/A
- MESO N/A
- Revenue Growth
- MSC 103.40
- MESO N/A
- 52 Week Low
- MSC $4.32
- MESO $1.61
- 52 Week High
- MSC $9.30
- MESO $12.18
- Technical
- Relative Strength Index (RSI)
- MSC 44.80
- MESO 55.85
- Support Level
- MSC $6.00
- MESO $8.52
- Resistance Level
- MSC $7.18
- MESO $12.18
- Average True Range (ATR)
- MSC 0.36
- MESO 0.63
- MACD
- MSC 0.00
- MESO 0.17
- Stochastic Oscillator
- MSC 18.64
- MESO 57.96
About MSC Studio City International Holdings Limited
Studio City International Holdings Ltd is a gaming, retail, and entertainment resort located in Cotai, Macau. It operates Studio City Casino with around 250 mass-market gaming tables; including 15 tables for VIP rolling chip operations, and 552 gaming machines. Studio City features luxury hotel rooms, diverse food and beverage establishments, and complementary retail space. In addition, the company offers non-gaming attractions, including the world's first figure-8 Ferris wheel, a deluxe nightclub and karaoke venue, a live performance arena, an outdoor and an indoor water park. Geographically, the company derives the majority of its revenue from the Macau region.
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.